Th e di spos ition of o r:1l iso trctinoin to th e skin and the effe cts of th e dru g o n th e vitamin A levels in se rum and skin we re studi ed in 17 patien ts w ith nod ul ocystic acne. All patients receiv ed 0.5 m g/ kg/ da y for 3 m o nth s and 8 patients continu ed treatm ent w ith 0.75 m g/ kg/ d ay for ano th er 3 month s. Th e parent dru g, the m aj or m etabo lite (4oxo-iso tretino in ), and 2 natural retin o id s (retin o l and deh ydroretino l) we re m o nito red in serum and bi o psies o f unin vo lved skin , usin g adsorptio n hi g h-press ure liquid chro m atog rap h y. D urin g the initi a13 month s of trea tment th e mean isotretin o in leve l in th e se rum was 145 ng/ ml and in th e epider. mis 73 ng/g. Th e co rres po ndin g valu es for 4oxo-i so tretinoin we re 615 and 113 ng/g, res pectively . Even -----------I sotre tin o in is a hi g hl y effe ctive re medy fo r seve re acne, and marked ly suppresses sebum secretion even in low doses II ,21.
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An o ther sy n thetic retin o id, ctretina te, kn own to impro ve a variet y of knatini zin g skin disorde rs, is not nea rl y as efTectivc as iso tre tin o in in acne \3 \. The reason for thi s differen ce in effect is no t understood ; no r is the p recise me chani sm of actio n or th e dr ug. When atte mptin g to elu cidate these m atters it is impo rta nt to keep in mind that isotretin o in pro bably lies in th e pathway of vita min A 1 (retin o l) m etabo li sm \4-TJ.
Vitamin A is esse nt ial fo r pro per differentiatio n of epithelia, in clu din g th ose linin g th e hair fo lli cles and th e sebaceo us g lands IS\. Altho ugh the fo lli cul ar keratini zatio n is disturbed both in vitam in A deficiency and in ac ne vul ga ri s !9 \, the impo rta nce o f hypov ita min osis A in the pathogenes is o f acne is still hi g hl y co ntroversial. Recentl y the se ru m concentratio ns o f retin o l and retin ol-b in d ing prote in (L < BP) and th e skin concentrati o ns of retinol were fou nd to be so mew hat lower in acne patien ts th an in hea lthy controls [1 0-12 \.
In the present stud y we address the q uestio n o f w he ther isotretino in th erapy inte rferes w ith the plas m a tran spo rt o f vita min A (in volvin g R BP and prea lbumin) o r w ith th e occurren ce oC2 pred o min ant fo rm s of vitamin A in th e skin , namely retinol and de hydro retin o l (v itam in A 2 ) \1 3 \. Additi o nall y, the se rum and skin k vcl s o f isotretin o in and its m ain m etaboli te were stu d ied by a novel hi gh-press ure li quid chro matography (HPLC) proced ure. aratio ns were w ithdraw n at least 3 weeks prior to isotre tinoin therapy . N o concomitant systemi c m ed ica tio n w as allo wed. Three fema les started w ith o ral contra ce pti ves 2 months before the trial and co ntinu ed to take them throughout the stud y. Two health y m ale subj ects served as pla cebo-treated contro ls. All patients were in good gene ral health and, except for a staphylococca l carbuncl e in 1. patient:, no co ncurrent diseases de velo ped . T he re was no dropout from the study . O ur patients took part in a mu lti cente r trial, the excellent clinical res ults of w hi ch wi ll be presented elsew here.
MATERIALS AND M ETH ODS

Patients
Written info rm ed consent was o btai ned from the pati ents, and the stud y was approved by the Ethi ca l Co mmittee of Uppsala Uni ve rsity.
Treattnent Ca psules co ntainin g 5, "I 0, or 20 m g of iso tretinoin (Roaccutane) in o il we re supplied by H o ffm ann-La Roche & Co. , AG , I3:~s el , Sw itze rl and. The initial ora l dose was 0.5 m g/k g/ d ay and the dru g was taken with m eals twi ce daily for 3 m o nths. At th e end of thi s peri od the dose w as adju sted acco rdin g to the clini ca l response. Thus, 8 pati ents with less than 66% imp rovem ent receive d 0 . 75 m g/ kg/day fo r another 3 m o nths, w hereas the o ther 9 patients stopped trea tment.
Place bo ca psules, not containin g iso tretino in, were provided by 1-l o ffman-La Roche and administered (5 per day) to the 2 hea lth y contro ls. Meth ods. T he foll ow in g retin oid stand ards were added: all-trailS retinol (p ea k '/), dchyd rorctin ol (peak 2), aromatic an al ogue of all-trail s retin ol (intern al standard ; peak 3), iso tn:tin oin (peak 4), ca rboxyli c acid of ctrctin ate (intern al stan dard ; p eak 8) and 4-oxo-iso trctin oin (p eak 12). Additional pea ks appea rin g durin g :uJJ iys is were: tretinoi n (p eak 5); I I , 13-d i-cis-tretin oin (pea k 6), 13cis ca rboxyli c acid of etrctinatc (peak 7), and --1ox o-tretin oin (pea k II ). Peaks 9 a11d 10 we re not iden tified. The base-line shifts in (b) at I U and I H min after sa mpl e injecti on (i11j) were th e res ults of a disco ntinuous change in so lvent mi xture gradients. Owin g to the hi gh exte nt of arti factll al isomeri za ti on of 4-oxo-isotrctinoin, the su1n of the heig hts of peaks 11 a111i 12 was related to the sum of pea ks 7 ami 8 for quantitati om . T he f1rst ext ra ct (co nta ining neu tral retin o ids) was ch ro m ateg rap hed isocratica ll y (Aow rate 1. 2 ml / min) in a mi xture of hexa ne and eth yl aceta te (85: 15 v/ v) containin g 0 .5% ethano l and 0.05% acetic ac id .
Tissue and Blood Collection
T he second ex trac t (containin g acidi c reri no ids) was chrom atog raphed in a discontinuo us g rad ient chang ing the hexane to eth yl aceta te rati o (v/v) fro m 93:7 to 85: 15 at 6 min after inj ectio n of the sa mpl e (the so lve nts were o th e rw ise ide ntica l. i.e., they con ta in ed 0.5% ethano l and 0.05% ace ti c acid). T he fl ow rate w as I .4 ml / min and th e ti m e be twee n inj ecti o ns (i ncl udin g reequilibra tio n) was 35 min . Other Analyses Se rum IUH' a n d prGllbuntin co n ce n t rat io ns we re m eas ured b y rad ial imm un o difti 1sio n J17 Ju sin g co mmercial rabbit a ntisera ( l k h r in~wc rkc AG, M a rbur~. Wes t G erm a n y). be low the detectio n limit of t he ass:~y (10 ng / g) . As seen in Fi g 3, in patients w ho con tinu ed to take iso trctin o in fo r an addit ion :d 3 m o n t hs, t he altered retin o l and dehydro rctin o l va luL'S p e rsisted unti l the dru g was d isco n tinu ed . l'retreatn1 e11t values we re u s u a ll y reg a ined w ithin I m o nth ~fter ccss:1tio n of t hcr:1py. Jn 2 p lace bo-treated contro ls th e epider m al va lues ch an ged by less th an 20% ove r a 6-weck peri od (m ea n con ce mra tion s of retinol / d e h ydro retin o l befo re and d urin g placebo: 162 / 52 n g / g and 189/ 4(J n g / g, respectively). T he sub cutan eo u s con centratio n of retin o l did n ot ch an ge significa ntl y durin g isotretino in tre:Hn 1e11t (m ea n va lues 2 I 07, 2Uo3, and 1733 n g/g , befo re, durin g , and afte r th erapy) . Sin ce the con- Initia l experiments showed t ha t in o rder to permit detection of s m a ll a m o unts of isot retin o in i11 the skin , t hi s co mpo un d had to be a n ea rly e luent fi·o m th e 1-l i'LC co lumn . Adso rpti o n (no rm alph a se) c hro nu tog raph y o n silica gel, performed w ith a dis co ntinuou s g radi en t, all owed simultam·o us ana lys is o f iso tre tin o in and 4-oxo-isotretin o in, w hi ch we re eluted in th at o rd er. A sin1ilar HPLC sys tem , but with o ut :1 g radi en t, was used fo r mc.JS uiT I11 eiH of re ti n o l J nd de h yd roretin o l. T his assa y y ielded essenti all y th e sa me res u lts as reverse-ph ase Hl'LC, bur gave so m ew hat hi g her se rum retin o l va lues than a Au oro m ctri c assay used prev io us ly [11] . T h e m ain disadv:mtages of the n o rm al-ph ase HJ>L C sys tem us ed we re th e lo ng run tin1 cs and the di fti cu ltics in achi ev in g co n s tant retention tim es dur ing g radi ent eluti o n, particubrl y w hen rc tinoids w ere assayed in far-ri ch sa mples .
In o rd e r to obta in a q u antitati ve recovery o f retin o ids fi·o m sk.in sa mpl es a h ydro ly ti c e x tra ctio n w as used. Fo r co ng ru en ce , the sera we re ana lyzed w ith the sa m e h yd ro lytic procedure. 13y O n the oth e r h and , we rece ntl y repo rted that e trc tin a te therapy redu ced th e epide rm al retin o l leve l and sli g htl y in c reased th e leve l of dchydro reti no l in the no rm al sk in of patients w ith ke rat ini zin g di so rd c1 ·s \1 4] . lsotretin o in , w hi ch indu ces si milar st ru ctural cha nges in epide rmi s (e .g., xe rosis, pee lin g, :111d dermatitis) as e tret in ate 13 ], had quite a different effect o n the ep id er m al vitamin A content. The co n ce n t rati o n of retin o l in the ep idermi s alm ost doubled and th e de h yd ro retin o l co n cc ntrn io n dec reased to o ne-fifth of the original va lue. T hese effects, w hi ch were revnsiblc afte r cessation of therapy and did not appe:J r during phccbo treatment, co uld fo r obv io us reasons n o r be the res ult of a chan ged pla s m a transpo rt of retin o l to th e skin . We find it more li ke ly that alterati o n s in the loca l v itamin A m etabo li s m arc in vo lved. Sin ce isotrcrinoin ca nn ot be co n ve rted to retin o l in th e ti ss ue 13 1 j. the in c rease in epidcn,na l retino l in duced by the tn.:a tmeJH is probab ly due eith er to s timulated uptake of retinol to kcratin ocy tcs or to inh_ ibitiOJ) of th e retinol metaboli sm in th e cell s.
T he f:1cto rs re g ulatin g the cp idc rnu l dchydrorctino l le ve l a rc v irt u all y unkn own. Dchydroretinol (o r its co n ge ne r in unhydrolyzcd s kin) is a n in situ m etaboli te of retino l w hi ch accumulates in co nn ec tion w ith epi d er mal h ypc rpr o life rat io n [II ,32-34 1. A situ atio n in w hi c h dchydrorctinol is decreased h as n ot previously been e n co un te red. 1-l o pcfull y, the inte ra ct ions bet wee n isotretino in and end ogeno us retinol and dehydroretinol, m ay be in s trumental in future in ves ti g~ti o n s of th e f.1cto rs rcg ul~tin g epiderma l vita min A m etabo li s m. THE J OU I~NA L l F INVESTIGATI VE DE I~MATOLOGY It is n o t known w h e th e r the c han ge in the epid e rm al vita min A compos iti o n induced b y isotrc tin o in therapy is specifi c for acne patients. In the prese nt seri es th e treatment rai sed th e ·dcercascd ep idermal retino l co n ce ntra ti o ns fo und in untrea ted acne patients 11 1], but there was no appa re nt cor rela ti o n betwee n th e clinical re spo n se to isotrc tin o in a nd th e c hange in e pider mal v ita min A co mp ositio n durin g treatment (res ults not s h ow n). H owever, this d ocs n ot excl ude th e poss ibility that the effects o n epitheli a l vitamin A a rc inv o lved in the m ec h ani sm of acti o n of isotretinoin .
